Candesartan cilexetil: An update of its use in essential hypertension

Drugs

Volumn 62, Issue 8, 2002, Pages 1253-1287

  Easthope, Stephanie E ^a   Jarvis, Blair ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Candesartan cilexetil; Hypertension; Pharmacodynamics; Pharmacokinetics; Therapeutic use; Tolerability

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ALBUMIN; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CALCIUM ANTAGONIST; CANDESARTAN; CANDESARTAN HEXETIL; CHYMASE; CV 15959; CYTOCHROME P450 2C9; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; ENALAPRIL; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; HYDROCHLOROTHIAZIDE; LOSARTAN; N(G) METHYLARGININE; RENIN; TAK 044; THIAZIDE DIURETIC AGENT; TRYPSIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BACKACHE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COUGHING; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INDICATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; ESSENTIAL HYPERTENSION; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; KIDNEY FAILURE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

EID: 0036271824     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262080-00016     Document Type: Review

References (173)

1. Angiotensin II receptor antagonists
2. Blocking the tissue renin-angiotensin system: The future cornerstone of therapy
3. Angiotensin II-receptor blockers: Clinical relevance and therapeutic role
4. Angiotensin II receptor blockers: Rreview of the binding characteristics
5. Candesartan cilexetil. A review of its use in essential hypertension
6. Candesartan cilexetil plus hydrochlorothiazide combination. A review of its use in hypertension
7. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil
8. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors
9. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) Pilot study
10. Candesartan in heart failure - Assessment of reduction in mortality and morbidity (CHARM): Rationale and design
11. Inhibition of rabbit aortic angiotensin II (All) receptor by CV-11974, a new nonpeptide AII antagonist
12. Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists
13. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H- tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116)
14. Chronic peripheral administration of the angiotensin II AT1 receptor antagonist candesartan blocks brain AT1 receptors
15. Pharmacologic properties of candesartan cilexetil - Possible mechanisms of long-acting antihypertensive action
16. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor
17. Renin-angiotensin system blockade improves endothelial dysfunction in hypertension
18. Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats
19. Preventrion of atherosclerosis by specific AT1-receptor blockade with candesartan cilexetil
20. Candesartan abrogates G protein-coupled receptors agonist-induced MAPK activation and cardiac myocyte hypertrophy
21. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture
22. Role of the angiotensin AT(1) receptor in rat aortic and cardiac PAI-1 gene expression
23. Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human cultured monocytes
24. The role of angiotensin II AT1-receptors in the regulation of the cerebral blood flow and brain ischaemia
25. Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats
26. Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury
27. Candesartan cilexetil reduces graft arteriosclerosis in aortic transplantation model in rat
28. Angiotensin II type 1-receptor antagonist candesartan cilexetil prevents left ventricular dysfunction in myocardial infarcted rats
29. The angiotensin II AT1 receptor antgonist candesartan at antihypertensive plasma concentrations reduces damage induced by ischemia-reperfusion
30. Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography
31. Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats
32. TCV-116, a newly developed angiotensin II receptor antagonist, induces regression of cardiac hypertrophy through suppression of the tissue renin-angiotensin system in spontaneously hypertensive rats
33. AT1 receptor antagonist, TCV 116, does not prevent cardiac hypertrophy in salt-loaded Dahl salt-sensitive rats
34. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-β1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats
35. Differential effects of imidapril and candesartan cilexetil on plasminogen activator inhibitor-1 expression induced by prolonged inhibition of nitric oxide synthesis in rat hearts
36. Effects of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis
37. Relative antihypertensive and glomeruloprotective efficacies of enalapril and candesartan cilexetil in the remnant kidney model
38. The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorder in rats
39. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors
40. Seven-transmembrane-spanning receptors and heart function
41. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin
42. Binding of the antagonist [H-3] candesartan to antagonist II AT (1) receptor-transfected Chinese hamster ovary cells
43. Angiotensin II type 1 receptor antagonists. Why do some of them produce insurmountable inhibition?
44. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers
45. Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man
46. Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man
47. Extent and duration of angiotensin II antagonistic activity of irbesartan and candesartan cilexetil
48. Dose-dependent blockade of the angiotension II type I receptor in normal volunteers: Incomplete and transient blockade by losartan 50 mg
49. Renal hemodynamic and hormonal responses to the angiotensin II antagonist candesartan
50. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan
51. Irbesartan results in more complete blockade of human renal AT1-receptor mediated effects than does candesartan cilexetil as evidenced by higher plasma renin levels
52. Candesartan cilexetil in hypertension: Effects of six weeks' treatment on haemodynamics, baroreceptor sensitivity and the renin-angiotensin-aldosterone system
53. A double-blind, crossover study of the antihypertensive efficacy of angiotensin 1I-receptor antagonists and their activation of the renin-angiotensin system
54. Irbesartan results in more complete blockade of human adrenal AT1-receptor mediated effects than does candesartan cilexetil as evidenced by blunted plasma aldosterone levels
55. Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension
56. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients
57. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect
58. Candesartan cilexetil and renal hemodynamics in hypertensive patients
59. Effects of candesartan on cardiac and arterial structure and function in hypertensive subjects
60. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension
61. Candesartan vs hydrochlorothiazide improves diastolic function in mild-to-moderate essential hypertension
62. Effects of candesartan cilexetil (TCV-116) on cerebral clood flow of hypertensive patients with cerebrovascular diseases
63. Antihypertensive treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in patients with mild hypertension and type II diabetes
64. Renal vascular respnses to captopril and to candesartan in patients with type 1 diabetes mellitus
65. Candesartan decreases proteinuria and improves creatinine clearance in hypertensive diabetic patients
66. Candersartan vs. amlodipine in double blind study in hypertensive patients with diabetic nephropathy
67. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study
68. The effect of TCV-116, an angiotensin II receptor antagonist, on lipid metabolism in patients with essential hypertension
69. Comparative potency of various AT1 antagonists using the Schild regression technique in man
70. Effects of four angiotensin II-receptor antagonists on fibrinolysis in postmenopausal women with hypertension
71. Left ventricular hypertrophy and angiotensin II antagonists
72. Comparative effects of the ACE inhibitor enalapril and the angiotensin II receptor antagonist candesartan on left ventricular hypertrophy (LVH) in essential hypertensive patients. Results of CATCH study
73. Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy
74. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy
75. Effects of candesartan on the proteinuria of chronic glomerulonephritis
76. Reduction of proteinuria - Combined effects of AT1-receptor blockade and ACE-inhibition
77. Effects on blood pressure, proteinuria and renal function of adding an angiotensin receptor antagonsit (candesartan, 8mgs) to an ACE inhibitor in normotensive patients with renal disease
78. Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension
79. Effects of an angiotensin II receptor antagonist TCV-116 (candesartan cilexetil) on renal function in essential hypertension
80. Angiotensin II-receptor-antagonism improves endothelium-mediated vasodilation in patients with coronary artery disease: Role of nitric oxide and bradykinin
81. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers
82. Candesartan cilexetil in haemodialysis patients
83. Pharmacokinetic study of candesartan cilexetil, an angiotensin II receptor antagonist, in patients with hepatic impairment
84. Bioavailability of candesartan is unaffected by food in healthy volunteers administered candesartan cilexetil
85. Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function
86. Pharmacokinetics, haemodynamics and safety of candesartan cilexetil in hypertensive patients undergoing haemodialysis
87. Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function
88. In vitro metabolism of candesartan cilexetil
89. Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers
90. Comparative pharmacokinetics of multiple-dose candesartan in subjects with and without impaired hepatic function
91. Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension - A population analysis
92. Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment
93. Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis
94. Pharmacokinetic drug interaction studies with candesartan cilexetil
95. Effects of candesartan cilexetil in patients with systemic hypertension
96. Effective dose range of candesartan cilexetil for systemic hypertension
97. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension
98. Comparison of candesartan versus enalapril in essential hypertension
99. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: Benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide
100. Antihypertensive treatment in elderly patients aged 75 years or over: A 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide
101. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension
102. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: A placebo- controlled, forced titration study
103. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension
104. Antihypertensive effects and tolerability of candesartan cilexetil alone and in combination with amlodipine
105. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension
106. Antihypertensive effect of candesartan and amlodipine assessed by home blood pressure
107. Efficacy and tolerability of candesartan cilexetil vs physican's choice: The real life study
108. A new approach to assessing antihypertensive therapy: Effect of treatment on pulse pressure
109. Antihypertensive efficacy of candesartan in comparison to losartan: The claim study
110. The effect of candesartan, felodipine or their combination on 24 h blood pressure and microalbuminuria
111. Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension
112. Efficacy and tolerability of candesartan cilexetil monotherapy or in combination with other antihypertensive drugs. Results of the AURA study
113. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: A clinical experience trial
114. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension
115. Effects of candesartan cilexetil in patients with severe systemic hypertension
116. Efficacy and tolerability of a combination tablet of candesartan cilexetil and hydrochlorothiazide in insufficiently controlled primary hypertension - Comparison with a combination of losartan and hydrochlorothiazide
117. A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy
118. Comparison of the efficacy and tolerability of combination tablets containing candesartan cilexetil and hydrochlorothiazide or losartan and hydrochlorothiazide in patients with moderate to severe hypertension. Results of the CARLOS-Study
119. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients
120. Combination therapy with candesartan cilexetil plus hydrochlorothiazide in patients unresponsive to low-dose hydrochlorothiazide
121. Combination therapy with candesartan cilexetil and hydrochlorothiazide in patients with systemic hypertension
122. Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy: A randomized double-blind crossover study
123. Efficacy and safety of candesartan cilexetil (TCV-116) in hypertensive patients with renal failure
124. Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: Candesartan cilexitil versus losartan
125. Efficacy and tolerability of candesartan in moderate and severe essential hypertension
126. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan
127. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II
128. Candesartan cilexetil vs losartan
129. Candesartan vs losartan
130. Angiotensin II antagonists for hypertension: Are there differences in efficacy?
131. The relationship between dose and antihypertensive effect for different AT1-receptor blockers
132. Antihypertensive effects of candesartan cilexetil, enalapril and placebo
133. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension
134. Comparsion of the efficacy and safety of candesartan cilexetil 4, 8 and 12mg with placebo and enalapril 10mg in patients with mild to moderate essential hypertension
135. Comparison of the antihypertensice efficacy and tolerability of candesartan cilexetil and angiotensin-converting enzyme inhibitor therapy in primary hypertension: The CHAMPION study
136. The SSA-profile, an instrument for assessment of subjective symptoms among hypertensives
137. The psychological general well-being (PGWB) index
138. Determining a minimal important change in a disease-specific Quality of Life Questionnaire
139. The effect of candesartan, felodipine or their combination on 24h ambulatory blood pressure
140. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population
141. Study on COgnition and Prognosis in the Elderly (SCOPE): Baseline characteristics
142. Study on COgnition and Prognosis in the Elderly (SCOPE)
143. The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion
144. Tolerance of candesartan cilexetil 4 and 8 mg with cancineurine inhibitors in renal transplant and hypertensive patients
145. Hypertension and stroke - Rationale behind the ACCESS trial. Acute Candesartan Cilexetil Evaluation in Stroke Survivors
146. Evaluation of candesartan cilexetil in black patients with systemic hypertension: The ABC trial
147. Effects of candesartan cilexetil on health-related quality of life in black patients with systemic hypertension in the ABC trial
148. Candesartan cilexetil: Safety and tolerability in healthy volunteers and patients with hypertension
149. Candesartan cilexetil is not associated with cough in hypertensive patients with enalapril-induced cough
150. Evaluation of clinical usefulness of TCV-116 (candesartan cilexetil) in patients with essential hypertension: A double-blind, parallel group-comparison study using enalapril maelate as control drag
151. Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma
152. The sixth report of the Joint National Committee on Detection Evaluation Treatment of High Blood Pressure
153. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context
154. British Hypertension Society guidelines for hypertension management 1999: Summary
155. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension
156. Health outcomes associated with antihypertensive therapies used as first-line agents
157. Effects of ACE inhibitors, calcium antagonists, and other blood- pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration
158. Angiotensin receptors and their antagonists
159. The importance of left ventricular hypertrophy in human hypertension
160. Assessment of prevalence of left ventricular hypertrophy in hypertension
161. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
162. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
163. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
164. Retinal neovascularization is prevented by blockade of the renin- angiotensin system
165. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes
166. The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme